Rasburicase and Tumor Lysis Syndrome: Lower Dosage, Consideration of Indications, and Hyperhydration

被引：17
|
作者：
Darmon, Michael [1 ]
Guichard, Isabelle [1 ]
Vincent, Francois [2 ]
机构：
[1] St Etienne Teaching Hosp, St Etienne, France
[2] Avicenne Teaching Hosp, Bobigny, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 03期
关键词：
SINGLE-DOSE RASBURICASE; 6; MG; ADULTS; HYPERURICEMIA; PROPHYLAXIS; MANAGEMENT; CANCER;
D O I：
10.1200/JCO.2010.32.6751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [31] Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients
    Eaddy, Michael
    Seal, Brian
    Tangirala, Muralikrishna
    Davies, Elizabeth Hackney
    O'Day, Ken
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (24) : 2110 - 2114
  • [32] Single 4.5mg Dose of Rasburicase for Tumor Lysis Syndrome In Adults
    Yim, Barbara
    Navaleza, Anne
    Haidau, Augustin
    Sreenivasappa, Shylendra
    Kassem, Mohammed A.
    Ciobanu, Bety C.
    Braik, Tareq
    Gaddh, Manila
    Rubinstein, Paul G.
    Shah, Moushmi
    Telfer, Margaret
    Catchatourian, Rose
    BLOOD, 2010, 116 (21) : 741 - 742
  • [33] Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome
    da Silva, Rodrigo Lopes
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (03) : 471 - 472
  • [34] Rasburicase for the treatment of tumor lysis in hematological malignancies
    Malaguarnera, Giulia
    Giordano, Maria
    Malaguarnera, Mariano
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (01) : 27 - 38
  • [35] Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era
    Toda, Yumiko
    Ashizawa, Masahiro
    Murahashi, Rui
    Nakashima, Hirotomo
    Ikeda, Takashi
    Kawaguchi, Shin-Ichiro
    Nagayama, Takashi
    Umino, Kento
    Minakata, Daisuke
    Morita, Kaoru
    Yamamoto, Chihiro
    Hatano, Kaoru
    Sato, Kazuya
    Fujiwara, Shin-Ichiro
    Ohmine, Ken
    Kanda, Yoshinobu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (06) : 660 - 666
  • [36] Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices
    Gilmore, Steven
    Carroll, Melissa
    Koselke, Elizabeth
    Hough, Shannon
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (05) : 867 - 872
  • [37] EFFICACY OF SINGLE DOSE RASBURICASE (1.5 MG) FOR PROPHYLAXIS AND MANAGEMENT OF TUMOR LYSIS SYNDROME
    Radhakrishnan, Venkatraman
    Philips, Ashwin
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [38] Professional practice evaluation of uses of rasburicase in tumor lysis syndrome in a French University Hospital
    Annereau, M.
    Fouche, C.
    Smulevici, A.
    Joly, A. C.
    Vekhoff, A.
    Isnard, F.
    Legrand, O.
    Tilleul, P.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2012, 34 (01) : 223 - 224
  • [39] A single 6 milligram dose of rasburicase for the management of tumor lysis syndrome in adults.
    McDonnell, A
    Hall, PD
    Lenz, K
    Hayslip, R
    Frei-Lahr, D
    PHARMACOTHERAPY, 2005, 25 (10): : 1470 - 1470
  • [40] Efficacy of single dose rasburicase in prophylaxis and treatment of tumor lysis syndrome: a metaanalysis.
    Feng, Xiaodong
    Dong, Kevin
    Dan Pham
    Inciardi, John
    Bhutada, Nilesh
    PHARMACOTHERAPY, 2012, 32 (10): : E222 - E222
12345